Cargando…

S311: EFFICACY OF INTRAVENOUS IRON TREATMENT FOR CANCER PATIENT WITH ANEMIA, RANDOMIZED CONTROLLED STUDY

Detalles Bibliográficos
Autores principales:	Ho Jang, Jun, Park, Kyunghwa, Yong Oh, Sung, Woo Lee, Hyun, Eom, Hyeon-Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428342/ http://dx.doi.org/10.1097/01.HS9.0000968156.12718.71

Ejemplares similares

S229: PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA: A PHASE III RANDOMIZED, CONTROLLED STUDY
por: Yahng, Seung-Ah, et al.
Publicado: (2023)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023)

S307: CEVIDOPLENIB (SKI-O-703), A NOVEL SYK INHIBITOR, REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS AND PREVENTS INTRAMYOCARDIAL SMALL ARTERIAL THROMBOSIS IN A MOUSE MODEL OF ANTIPHOSPHOLIPID SYNDROME
por: Jang, Eunkyeong, et al.
Publicado: (2023)

S289: PPP1R1B BINDS IRON REGULATORY PROTEINS AND MODULATES IRON CELLULAR CONTENT
por: Calvo López, Laura, et al.
Publicado: (2023)

S277: IPSC DISEASE MODELS TO STUDY AND TREAT DIAMOND-BLACKFAN ANEMIA SYNDROME (DBAS)
por: Clark, Chantal, et al.
Publicado: (2023)

S288: DIFFERENTIAL RECOVERY OF MACROPHAGE IRON DEFICIENCY BY ORAL IRON FORMULATIONS DETERMINES CELL INFLAMMATORY ACTIVATION IN ANEMIC CONDITIONS
por: Antypiuk, Ada, et al.
Publicado: (2023)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
por: Prabahran, Ashvind, et al.
Publicado: (2023)

S266: DIFFERENT MOLECULAR VASO-OCCLUSIVE TRIGGERS STIMULATE DISTINCT VASO-OCCLUSIVE PROFILES: IN VIVO RESULTS FROM MICE WITH SICKLE CELL ANEMIA
por: Gushiken, Lucas F. S., et al.
Publicado: (2023)

S176: FUNCTIONAL AND ANTIGEN-SPECIFIC CHARACTERIZATION OF IMMUNE CELLS AT THE SINGLE-CELL LEVEL REVEALS CONVERGENCE OF ADAPTIVE AND INNATE IMMUNITY IN IMMUNE APLASTIC ANEMIA
por: Huuhtanen, Jani, et al.
Publicado: (2023)

S286: TARGETING CONDITIONING-ELICITED NON-TRANSFERRIN-BOUND IRON BY TMPRSS6 SILENCING IMPROVES BONE MARROW TRANSPLANT OUTCOME
por: Antypiuk, Ada, et al.
Publicado: (2023)

S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bordini, Jessica, et al.
Publicado: (2023)

Effects of intravenous iron monotherapy for patients with iron deficient anemia undergoing total knee arthroplasty
por: Shin, Kyun-Ho, et al.
Publicado: (2020)

S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)
por: Dimopoulos, Meletios A., et al.
Publicado: (2023)

S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA
por: LI, Zongru, et al.
Publicado: (2023)

S281: TMPRSS6 INHIBITION WITH A MONOCLONAL ANTIBODY IMPROVES RED BLOOD CELL HEALTH AND IRON OVERLOAD IN A MOUSE MODEL OF BETA-THALASSEMIA
por: Lob, Heinrich, et al.
Publicado: (2023)

P311 First reported case of Cladosporium liver abscess in immunocompromised host
por: Xuan, Tuang Wei, et al.
Publicado: (2022)

S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023)

S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
por: Kenet, Gili, et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2011)

S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
por: Jacobs, Ryan, et al.
Publicado: (2023)

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

S209: TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS
por: Jungius, Sarah, et al.
Publicado: (2023)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
por: Xuying, Pei, et al.
Publicado: (2023)

S232: EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK
por: Choquet, Sylvain, et al.
Publicado: (2023)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

S112: THE EFFECT OF IMMUNOGLOBULIN PROPHYLAXIS ON INFECTIOUS MORBIDITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
por: Thus, Kirsten, et al.
Publicado: (2023)

S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS
por: Gill, Harry, et al.
Publicado: (2023)

S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
por: Zhang, Yi, et al.
Publicado: (2023)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Scully, Marie, et al.
Publicado: (2023)

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
por: Shi, Yan, et al.
Publicado: (2023)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

S272: SAFETY AND EFFICACY OF RM-001 IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: EARLY RESULTS FROM THE ONGOING OF AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS
por: Liu, Rongrong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p5letcofc02901lcr47b8nkgdl